Insider · CIK 0001747528
Steven George Hughes
Files at RNA (Avidity Biosciences, Inc.), RNA (Atrium Therapeutics, Inc.). First filing Jan 23, 2025, latest Jan 23, 2026.
In brief
Steven George Hughes files SEC Form 4 as officer at RNA (Avidity Biosciences, Inc.), and also at RNA (Atrium Therapeutics, Inc.). Since Jan 23, 2025, Steven George Hughes has reported 0 open-market buys worth $0 and 10 open-market sells worth $4.9M, the latest filed on Jan 23, 2026.
A track record needs three past buys with six months of prices behind them; Steven George Hughes has 0, so none is measured yet.
The newest scored trade: sold $355k of RNA on Jan 21, 2026, filed Jan 23, 2026, scored 30 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $631k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Avidity Biosciences, Inc. | $355k 4,895 shares | -13% | - | |
| 21Weak | Avidity Biosciences, Inc. | $171k 2,373 shares | -6% | - | |
| 0Weak | Avidity Biosciences, Inc. | $105k 2,209 shares | -5% | - | |
| 4Weak | Avidity Biosciences, Inc. | $90k 2,208 shares | -5% | - | |
| 3Weak | Avidity Biosciences, Inc. | $70k 1,542 shares | -4% | - | |
| 5Weak | Avidity Biosciences, Inc. | $102k 2,208 shares | -5% | - | |
| 3Weak | Avidity Biosciences, Inc. | $72k 1,542 shares | -4% | - | |
| 40Moderate | Avidity Biosciences, Inc. | $3.5M 81,434 shares | -97% | - | |
| 29Weak | Avidity Biosciences, Inc. | $297k 9,578 shares | -12% | - | |
| 20Weak | Avidity Biosciences, Inc. | $113k 3,947 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | 9,709 0.01% of outstanding | $449k | Aug 13, 2025 | $3.5M |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | 81,434 0.07% of outstanding | $3.1M | Aug 6, 2025 | none |
Transactions
Every row this insider has filed, 45 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | RNA Atrium Therapeutics, Inc. | FTax withholding Common Stock | -21,459 | $8.95 | $192k | 51,638 | 21 d ago |
| Apr 20, 2026 | RNA Atrium Therapeutics, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 73,097 | Apr 22, 2026 |
| Apr 20, 2026 | RNA Atrium Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 22, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -115,857 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -73,342 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -74,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -49,333 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -68,458 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 27, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,017 | $72.45 | $146k | 34,477 | Jan 23, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,878 | $72.45 | $209k | 31,599 | Jan 23, 2026 |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,373 | $72.23 | $171k | 36,494 | Jan 9, 2026 |
| Oct 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +2,209 | $10.16 | $22k | 41,076 | Oct 24, 2025 |
| Oct 22, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,209 | $47.54 | $105k | 38,867 | Oct 24, 2025 |
| Oct 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,209 | $0.00 | $0 | 68,458 | Oct 24, 2025 |
| Sep 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +2,208 | $10.16 | $22k | 41,075 | Sep 23, 2025 |
| Sep 22, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,208 | $40.58 | $90k | 38,867 | Sep 23, 2025 |
| Sep 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,208 | $0.00 | $0 | 70,667 | Sep 23, 2025 |
| Sep 15, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +1,542 | $6.57 | $10k | 40,409 | Sep 17, 2025 |
| Sep 15, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,542 | $45.41 | $70k | 38,867 | Sep 17, 2025 |
| Sep 15, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,542 | $0.00 | $0 | 49,333 | Sep 17, 2025 |
| Aug 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +2,208 | $10.16 | $22k | 41,075 | Aug 22, 2025 |
| Aug 22, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,208 | $46.40 | $102k | 38,867 | Aug 22, 2025 |
| Aug 22, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,208 | $0.00 | $0 | 72,875 | Aug 22, 2025 |
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +1,542 | $6.57 | $10k | 40,409 | Aug 15, 2025 |
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,542 | $46.66 | $72k | 38,867 | Aug 15, 2025 |
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,542 | $0.00 | $0 | 50,875 | Aug 15, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +11,283 | $15.96 | $180k | 84,133 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -11,283 | $42.74 | $482k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +12,334 | $6.57 | $81k | 85,184 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -12,334 | $42.74 | $527k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +6,167 | $22.47 | $139k | 79,017 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -6,167 | $42.74 | $264k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +17,667 | $10.16 | $179k | 90,517 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -17,667 | $42.74 | $755k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -33,983 | $42.74 | $1.5M | 38,867 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,283 | $0.00 | $0 | 73,342 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,334 | $0.00 | $0 | 52,417 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,167 | $0.00 | $0 | 74,000 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,667 | $0.00 | $0 | 75,083 | Aug 8, 2025 |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -9,578 | $31.06 | $297k | 72,850 | Mar 21, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,915 | $28.60 | $55k | 84,460 | Jan 23, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,032 | $28.59 | $58k | 82,428 | Jan 23, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 86,375 | Jan 8, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 8, 2025 |
Questions about Steven George Hughes
Answered from the filings on this page, as of the latest one.
Is Steven George Hughes buying or selling?
In the last 12 months Steven George Hughes reported 0 open-market buys worth $0 and 3 open-market sells worth $631k on SEC Form 4; the latest was sold $355k of RNA on Jan 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Steven George Hughes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steven George Hughes has 0.
Where does Steven George Hughes file Form 4?
Steven George Hughes has filed Form 4 at RNA (Avidity Biosciences, Inc.) as Chief Medical Officer; RNA (Atrium Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.